Home › Hereditary Sensory and Autonomic Neuropathies › Oregon › Portland
Hereditary Sensory and Autonomic Neuropathies clinical trials in Portland, OR
4 studies for Hereditary Sensory and Autonomic Neuropathies are looking for participants at sites in and around Portland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
RecruitingPhase 2
- VA Portland Health Care System, Portland, OR, Portland
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Oregon Health & Science University, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Providence Cancer Institute Franz Clinic, Portland
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RecruitingPhase 2
- Northwest Cancer Specialists, P.C., Portland
Hereditary Sensory and Autonomic Neuropathies trials in other cities
- San Antonio, TX7 studies
- Arlington, VA7 studies
- Boston, MA6 studies
- New York City, NY6 studies
- Nashville, TN6 studies
- Houston, TX5 studies
- Philadelphia, PA5 studies
- Ann Arbor, MI4 studies
- Pittsburgh, PA4 studies
- Washington, DC4 studies
- San Francisco, CA3 studies
- Los Angeles, CA3 studies
Other studies in Portland
- Non-Small Cell Lung Cancer46 studies
- Cancer (all types)34 studies
- Breast Cancer33 studies
- Prostate Cancer33 studies
- Metastatic Cancer29 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Lung Cancer26 studies
- Acute Myeloid Leukemia25 studies
- Endometrial Cancer24 studies
- Head and Neck Squamous Cell Carcinoma19 studies
- Pancreatic Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.